Hence, Fernandes et al. (52), have observed that the blockade of PSGL-1 alone is sufficient to significantly mitigate the formation of platelet-monocyte complexes (PMCs) in patients with coronary syndromes (patients with acute coronary syndrome and those with complications after percutaneous coronary intervention). This evidence concerns the gene SELPLG and acute coronary syndrome.